When it comes to the Life Sciences sector, the challenges faced by board members take on a whole new level of complexity. #boardsinlifesciences #pharma #medtech #biotech #boards #boardmember https://lnkd.in/dt_nM_uq

Interesting perspectives on navigating board roles in Pharma, MedTech & BioTech.

“Novartis Loses Bid for Preliminary Injunction Against MSN Pharmaceuticals.” Read our latest Life Sciences Blog post by Rhett Ramsey and Joe Mallon, Ph.D. here: https://lnkd.in/gj6N7WZ3   #KnobbeMartens #IPLaw #LifeSciences #Biotechnology   

Check out the latest episode of The BioCentury Show with new BIO (Biotechnology Innovation Organization) President & CEO John F. Crowley. ✅ Watch: https://lnkd.in/d-Fr_KRD John speaks with my BioCentury Inc. colleague Steve Usdin about several topics, including: ➢ Why BIO's position on the #Biosecure Act and WuXi AppTec and WuXi Biologics has changed. ➢ Why FDA should create a rare diseases center of excellence. ➢ Why BIO is planning "fly out" visits to cities around the U.S. ➢ Where common ground can be found between the biotech industry and Capitol Hill. ➢ How BIO plans to demonstrate the unintended consequences of the #IRA on drug development. And much more.... Watch or listen on YouTube. #biotech #biopharma #drugdevelopment #drugpricing #decoupling

Webinar Today!!! Discover the benefits of growing protein crystals in Space, and learn from the scientific data of two Kirara missions onboard the #ISS.

CellRev have been working with C2C12 cells for several years now in an effort to demonstrate true continuous processing of adherent cells. Read our case study to understand how we are facilitating the transition to continuous processing. https://hubs.ly/Q02c-y-H0 We have now shown compatibility with several cell lines including VERO Cells, iPSCs, and Fibroblasts. Get in touch on enquiry@cellrev.co.uk to discuss your requirements #cellmanufacturing #celltherapy #biomanufacturing #cellculture #bioprocessing #processautomation #biosciences #biotechnology #biopharma #pharma #biotech #innovation #biotechnology #bioengineering

In my conversation with Fraiser Kansteiner and Fierce Pharma at #FierceJPMWeek I plan to share more information about strategic decisions made in my first year as CEO of Vir Biotechnology, Inc., including expanding our focus and harnessing the power of our proven antibody platform into additional areas including viral-associated and immune-mediated diseases. With the progress already made in our #HDV and #HBV clinical programs, we are well positioned to leverage Vir’s in-house immunology and virology expertise to help transform the lives of millions of patients worldwide. #Patientsarewaiting

Have you downloaded the 2023 Horizons: Life Sciences report? It’s not too late to get all the insights into the current and future state the life sciences industry. We asked and more than 500 industry professionals answered with the trends and challenges they are currently facing. Their insights combined with in-depth analysis from CRB’s leading experts, this report is a must-have for anyone who works in the life sciences industry. Download it for free here: https://hubs.la/Q021S-DY0 For a preview, check out Peter Walter’s Q&A with BioPharma-Reporter at the link below. #LifeSciences #Biopharma #PharmaceuticalManufacturing #Biotech #Industry40 #CRBHorizons

EarthRate ESG Pharma and Biotech weekly (29.12.2023): • US hospital admissions increased to 29.000 in pre-Christmas week • Covid-deaths increase in Italy and Russia #EarthRate #esginvesting #pharma #biotech

After several days of meetings and valuable discussions at the 2024 PCMA Conference, Archbow gathered these essential takeaways for your pharma organization to consider. What do you think? Leave a comment below. We can help your organization understand the dynamic market access changes in 2024 and beyond and what that means to your market access strategy. Contact us today to learn more. #pharma #biotech #marketaccess